Recently, the phase 2 CAPAP lung trial reported that 1st–line camrelizumab (an anti–PD–1 antibody) combined with apatinib and albumin paclitaxel produced encouraging efficacy (ORR, 73.1%) and acceptable safety for advanced non–squamous NSCLC (61). This evidence concerns the gene ALB and non-small cell lung carcinoma.